NCT04211415View on ClinicalTrials.gov

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

March 14, 2020

Study Completion Date

December 18, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

DS-2741a

Single, subcutaneous injection (upper arm, upper part of the thigh, or abdominal wall in principle) administered weekly for 4 weeks

DRUG

Placebo

Single, subcutaneous injection administered weekly for 4 weeks

Trial Locations (1)

Unknown

Osaka Pharmacology Clinical Research Hospital, Osaka

Sponsors
All Listed Sponsors
lead

Daiichi Sankyo Co., Ltd.

INDUSTRY